Correlation Between Protagonist Therapeutics and Eterna Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Protagonist Therapeutics and Eterna Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Protagonist Therapeutics and Eterna Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Protagonist Therapeutics and Eterna Therapeutics, you can compare the effects of market volatilities on Protagonist Therapeutics and Eterna Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Protagonist Therapeutics with a short position of Eterna Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Protagonist Therapeutics and Eterna Therapeutics.

Diversification Opportunities for Protagonist Therapeutics and Eterna Therapeutics

0.68
  Correlation Coefficient

Poor diversification

The 3 months correlation between Protagonist and Eterna is 0.68. Overlapping area represents the amount of risk that can be diversified away by holding Protagonist Therapeutics and Eterna Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eterna Therapeutics and Protagonist Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Protagonist Therapeutics are associated (or correlated) with Eterna Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eterna Therapeutics has no effect on the direction of Protagonist Therapeutics i.e., Protagonist Therapeutics and Eterna Therapeutics go up and down completely randomly.

Pair Corralation between Protagonist Therapeutics and Eterna Therapeutics

Given the investment horizon of 90 days Protagonist Therapeutics is expected to generate 0.43 times more return on investment than Eterna Therapeutics. However, Protagonist Therapeutics is 2.34 times less risky than Eterna Therapeutics. It trades about 0.05 of its potential returns per unit of risk. Eterna Therapeutics is currently generating about -0.47 per unit of risk. If you would invest  4,039  in Protagonist Therapeutics on September 18, 2024 and sell it today you would earn a total of  107.00  from holding Protagonist Therapeutics or generate 2.65% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy95.24%
ValuesDaily Returns

Protagonist Therapeutics  vs.  Eterna Therapeutics

 Performance 
       Timeline  
Protagonist Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Protagonist Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong technical and fundamental indicators, Protagonist Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.
Eterna Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Eterna Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Protagonist Therapeutics and Eterna Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Protagonist Therapeutics and Eterna Therapeutics

The main advantage of trading using opposite Protagonist Therapeutics and Eterna Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Protagonist Therapeutics position performs unexpectedly, Eterna Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eterna Therapeutics will offset losses from the drop in Eterna Therapeutics' long position.
The idea behind Protagonist Therapeutics and Eterna Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Other Complementary Tools

Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance